oxybutynin has been researched along with HPV Infection in 1 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Adverse events and adverse drug reactions, the concentrations of FIT039, and surface area of cutaneous warts were evaluated." | 6.90 | Safety and Plasma Concentrations of a Cyclin-dependent Kinase 9 (CDK9) Inhibitor, FIT039, Administered by a Single Adhesive Skin Patch Applied on Normal Skin and Cutaneous Warts. ( Amino, Y; Asada, R; Hagiwara, M; Kabashima, K; Nomura, T; Sawada, T; Sumi, E; Tada, H; Uozumi, R; Yonezawa, A, 2019) |
| " Adverse events and adverse drug reactions, the concentrations of FIT039, and surface area of cutaneous warts were evaluated." | 2.90 | Safety and Plasma Concentrations of a Cyclin-dependent Kinase 9 (CDK9) Inhibitor, FIT039, Administered by a Single Adhesive Skin Patch Applied on Normal Skin and Cutaneous Warts. ( Amino, Y; Asada, R; Hagiwara, M; Kabashima, K; Nomura, T; Sawada, T; Sumi, E; Tada, H; Uozumi, R; Yonezawa, A, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sumi, E | 1 |
| Nomura, T | 1 |
| Asada, R | 1 |
| Uozumi, R | 1 |
| Tada, H | 1 |
| Amino, Y | 1 |
| Sawada, T | 1 |
| Yonezawa, A | 1 |
| Hagiwara, M | 1 |
| Kabashima, K | 1 |
1 trial available for oxybutynin and HPV Infection
| Article | Year |
|---|---|
Safety and Plasma Concentrations of a Cyclin-dependent Kinase 9 (CDK9) Inhibitor, FIT039, Administered by a Single Adhesive Skin Patch Applied on Normal Skin and Cutaneous Warts.
Topics: Adhesives; Administration, Cutaneous; Adult; Aged; Cryotherapy; Cyclin-Dependent Kinase 9; Female; H | 2019 |